BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Holaira Closes $10 Million in Series C Financing


2/11/2013 7:25:12 AM

MINNEAPOLIS, MN--(Marketwire - February 11, 2013) - Holaira, Inc., formerly Innovative Pulmonary Solutions, Inc. (IPS), a developer of medical devices to treat obstructive lung diseases, today announced the completion of its Series C private equity financing, totaling $10 million. All of Holaira's existing venture investors, Advanced Technology Ventures, Morgenthaler Ventures, Split Rock Partners, and Versant Ventures, participated in this round. Proceeds from this financing will be used to support the continued development of Holaira's minimally invasive products.

Holaira is working on a novel catheter-based system for a procedure called Targeted Lung Denervation, that has the potential to make breathing easier for patients with chronic obstructive pulmonary disease (COPD). Chronic Obstructive Pulmonary Disease (COPD) is one of the leading, yet under-recognized, causes of morbidity and mortality worldwide. It is characterized by a persistent airflow limitation that is progressive and interferes with normal breathing. Worldwide, more than 64 million people have COPD(1) with more than 13 million adults diagnosed in the US.(2)

"The completion of this financing signals continued confidence in the direction of our program to develop a system to enable a minimally invasive bronchoscopic treatment for COPD," said Dennis Wahr, M.D., president and chief executive officer of Holaira. "Our board of directors remains unchanged and I'm pleased that Mike Carusi of Advanced Technology Ventures, Mark Deem of The Foundry, Kirk Nielsen of Versant Ventures, Hank Plain of Morgenthaler Ventures, and Dave Stassen of Spilt Rock Partners will serve alongside me."

Concurrent with the financing milestone, Dr. Wahr announced the opening of the new corporate headquarters in Minneapolis, MN, under the new corporate name, Holaira.

"The relocation of the company, along with our new corporate identity, sets the stage for the next level of product development and our future clinical trials," continued Dr. Wahr.

About Holaira - Holaira, Inc. (formerly Innovative Pulmonary Solutions, Inc.) is a privately held lung denervation company developing minimally invasive products to make breathing easier for patients suffering from obstructive lung diseases. Founded in 2008, Holaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity and quality of life for patients with chronic obstructive pulmonary disease.

(1) World Health Organization Fact Sheet No 315, November 2011
(2) American Lung Association, COPD Fact Sheet, February 2011


Contact Information
Lorraine Marshall Wright
Holaira, Inc.
(206) 605-4553
Email Contact



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES